2022 Full Year Results



2022 was a transition year for Barco. We managed to bring our business back on a successful track, ready for our further growth ambitions.

An Steegen and Charles Beauduin CEOs Barco

Healthcare


Sales In millions of euro

EBITDA In millions of euro

38.4

2020 2021 2022

+71% vs 2021



+31% vs 2021

Strong demand in both Diagnostic Imaging and Surgical & Modality. Sales were up thanks to replacements in radiology and resumption of the mammography market. Digital operating rooms gained momentum, as well as large modality projects.



EBITDA

In millions of euro

2020 2021 2022

+316% vs 2021

Earnings per share € 0.84

Proposed dividend € 0.44

32% topline growth with significant profitability improvement,

positioning Barco well for long-term profitable growth

+10% vs 2021

60.7

+8% vs 2021

€ 126.5 M 12% of sales


50%

ECO labelled revenue

Enterprise

+32% vs 2021

Sales In millions of euro




+36% vs 2021

Meeting Experience accelerated in all regions supported by the return-to-the-office wave and growing momentum for video-enabled hybrid meetings. Large Video Walls was fueled by deployments of control rooms in Americas and **EMEA**


Entertainment

Sales In millions of euro



+29% vs 2021

FBITDA In millions of euro



+28% vs 2021

Solid demand for Barco's all-laser cinema projection portfolio, ramping up deliveries as supply chain constraints eased in the second half of the year. Immersive Experience had a record year with strong uptake for fixed installations in museums, theme parks and projection mapping.

Outlook for FY2023

The following statements are forward looking on a like-for-like basis and actual results may differ materially

Assuming stabilizing macro-economic conditions, management confirms its expectation of sales growth between 10 and 15% for 2023 versus the previous year.

The EBITDA margin is expected to further improve and move above 14% for full year 2023, reflecting operating leverage on higher sales and an increase in gross margin as a result of the further easing of the supply chain constraints.

